Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performance status assessed with the use of Eastern Cooperativ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Damian Mojsak, Beata Kuklińska, Michał Dębczyński, Robert Marek Mróz
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2021
Materias:	non-small cell lung cancer immunotherapy performance status. Medicine R
Acceso en línea:	https://doaj.org/article/33951a72defa418a95258e7273536311
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33951a72defa418a95258e7273536311
record_format	dspace
spelling	oai:doaj.org-article:33951a72defa418a95258e72735363112021-12-02T17:18:57ZImmunotherapy in patients with non-small cell lung cancer with ECOG PS 21428-25261897-430910.5114/wo.2021.105031https://doaj.org/article/33951a72defa418a95258e72735363112021-04-01T00:00:00Zhttps://www.termedia.pl/Immunotherapy-in-patients-with-non-small-cell-lung-cancer-with-ECOG-PS-2,3,43720,1,1.htmlhttps://doaj.org/toc/1428-2526https://doaj.org/toc/1897-4309Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performance status assessed with the use of Eastern Cooperative Oncology Group Performance Status (ECOG PS) score. Patients with ECOG PS 2 represent a significant proportion of the cancer population, one which is overlooked in most clinical trials of immunotherapy. Often, a reduced performance status is the only factor that excludes the patient from treatment with immunotherapy. Choosing the optimal method of treatment in patients with a worse general condition and with multiple diseases may be a significant problem for the doctor. Assessment of performance status may be a particular problem because not every patient has a worse PS score for the same reasons. In this study, we analyse the results of treatment of patients with a poorer performance status to date, and we present tools that improve the precise assessment of the degree of the performance status, which may enable more patients to access novel lung cancer treatments.Damian MojsakBeata KuklińskaMichał DębczyńskiRobert Marek MrózTermedia Publishing Housearticlenon-small cell lung cancer immunotherapy performance status.MedicineRENContemporary Oncology, Vol 25, Iss 1, Pp 53-56 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer immunotherapy performance status. Medicine R
spellingShingle	non-small cell lung cancer immunotherapy performance status. Medicine R Damian Mojsak Beata Kuklińska Michał Dębczyński Robert Marek Mróz Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
description	Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performance status assessed with the use of Eastern Cooperative Oncology Group Performance Status (ECOG PS) score. Patients with ECOG PS 2 represent a significant proportion of the cancer population, one which is overlooked in most clinical trials of immunotherapy. Often, a reduced performance status is the only factor that excludes the patient from treatment with immunotherapy. Choosing the optimal method of treatment in patients with a worse general condition and with multiple diseases may be a significant problem for the doctor. Assessment of performance status may be a particular problem because not every patient has a worse PS score for the same reasons. In this study, we analyse the results of treatment of patients with a poorer performance status to date, and we present tools that improve the precise assessment of the degree of the performance status, which may enable more patients to access novel lung cancer treatments.
format	article
author	Damian Mojsak Beata Kuklińska Michał Dębczyński Robert Marek Mróz
author_facet	Damian Mojsak Beata Kuklińska Michał Dębczyński Robert Marek Mróz
author_sort	Damian Mojsak
title	Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
title_short	Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
title_full	Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
title_fullStr	Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
title_full_unstemmed	Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
title_sort	immunotherapy in patients with non-small cell lung cancer with ecog ps 2
publisher	Termedia Publishing House
publishDate	2021
url	https://doaj.org/article/33951a72defa418a95258e7273536311
work_keys_str_mv	AT damianmojsak immunotherapyinpatientswithnonsmallcelllungcancerwithecogps2 AT beatakuklinska immunotherapyinpatientswithnonsmallcelllungcancerwithecogps2 AT michałdebczynski immunotherapyinpatientswithnonsmallcelllungcancerwithecogps2 AT robertmarekmroz immunotherapyinpatientswithnonsmallcelllungcancerwithecogps2
_version_	1718381078432972800

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Ejemplares similares